No information is available on the clinical use of erlotinib during breastfeeding. Because erlotinib is 93% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 36 hours and it might accumulate in the infant. It is also given in combination with gemcitabine for pancreatic cancer, which may increase the risk to the infant. The manufacturer recommends that breastfeeding be discontinued during erlotinib therapy and for 2 weeks after the final dose.
关于厄洛替尼在母乳喂养期间的临床应用尚无可用信息。由于厄洛替尼与血浆蛋白的结合率为93%，乳汁中的含量可能较低。然而，其半衰期约为36小时，可能会在婴儿体内蓄积。它还与吉西他滨联合用于治疗胰腺癌，这可能会增加对婴儿的风险。制造商建议在厄洛替尼治疗期间及最后一剂后2周内停止母乳喂养。
